Have a feature idea you'd love to see implemented? Let us know!

EDIT Editas Medicine Inc

Price (delayed)

$2.37

Market cap

$195.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.54

Enterprise value

$138.29M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights

Editas Medicine's gross profit has soared by 151% YoY but it has decreased by 8% from the previous quarter

The revenue has soared by 151% year-on-year but it has declined by 8% since the previous quarter

EDIT's equity has dropped by 51% year-on-year and by 24% since the previous quarter

Editas Medicine's quick ratio has decreased by 39% YoY and by 2.4% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://www.editasmedicine.com

Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of EDIT

Market

Shares outstanding

82.55M

Market cap

$195.64M

Enterprise value

$138.29M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.11

Price to sales (P/S)

3.17

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2.24

Earnings

Revenue

$61.76M

EBIT

-$228.54M

EBITDA

-$222.64M

Free cash flow

-$191.36M

Per share

EPS

-$2.54

Free cash flow per share

-$2.32

Book value per share

$2.13

Revenue per share

$0.75

TBVPS

$3.97

Balance sheet

Total assets

$327.57M

Total liabilities

$151.93M

Debt

$38.49M

Equity

$175.63M

Working capital

$198.79M

Liquidity

Debt to equity

0.22

Current ratio

3.75

Quick ratio

3.67

Net debt/EBITDA

0.26

Margins

EBITDA margin

-360.5%

Gross margin

100%

Net margin

-341%

Operating margin

-370%

Efficiency

Return on assets

-51%

Return on equity

-80.1%

Return on invested capital

-78.1%

Return on capital employed

-89.5%

Return on sales

-370.1%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EDIT stock price

How has the Editas Medicine stock price performed over time

Intraday

-1.66%

1 week

-14.44%

1 month

-36.97%

1 year

-76.58%

YTD

-76.6%

QTD

-30.5%

Financial performance

How have Editas Medicine's revenue and profit performed over time

Revenue

$61.76M

Gross profit

$61.76M

Operating income

-$228.52M

Net income

-$210.57M

Gross margin

100%

Net margin

-341%

Editas Medicine's gross profit has soared by 151% YoY but it has decreased by 8% from the previous quarter

The revenue has soared by 151% year-on-year but it has declined by 8% since the previous quarter

The net margin has soared by 57% YoY but it has contracted by 18% from the previous quarter

EDIT's operating margin has surged by 56% year-on-year but it is down by 16% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation

P/E

N/A

P/B

1.11

P/S

3.17

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

2.24

EDIT's EPS is down by 9% since the previous quarter but it is up by 6% year-on-year

EDIT's P/B is 67% below its 5-year quarterly average of 3.4 and 42% below its last 4 quarters average of 1.9

EDIT's equity has dropped by 51% year-on-year and by 24% since the previous quarter

The revenue has soared by 151% year-on-year but it has declined by 8% since the previous quarter

The P/S is 91% less than the 5-year quarterly average of 37.0 and 56% less than the last 4 quarters average of 7.2

Efficiency

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 57% year-on-year but it is down by 16% since the previous quarter

The ROE has decreased by 48% YoY and by 28% from the previous quarter

Editas Medicine's ROA has decreased by 32% YoY and by 21% from the previous quarter

EDIT's return on invested capital is down by 28% year-on-year and by 26% since the previous quarter

Dividends

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time

EDIT's total assets is 116% higher than its total liabilities

Editas Medicine's quick ratio has decreased by 39% YoY and by 2.4% QoQ

The current ratio has contracted by 39% YoY and by 2.6% from the previous quarter

The debt is 78% less than the equity

The company's debt to equity has surged by 120% YoY and by 29% QoQ

EDIT's equity has dropped by 51% year-on-year and by 24% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.